. 2013 Jul 14;260(10):2472–2480. doi: 10.1007/s00415-013-6979-y

Table 1.

Raw percentages of patients free from relapses to relative change versus placebo associated with teriflunomide treatment (TEMSO modified-ITT population)

	Placebo (n = 363)	Teriflunomide 7 mg (n = 365)	Teriflunomide 14 mg (n = 358)	Relative change (%)^a
	Placebo (n = 363)	Teriflunomide 7 mg (n = 365)	Teriflunomide 14 mg (n = 358)	7 mg vs. placebo	14 mg vs. placebo	7 mg vs. 14 mg
Patients free of relapses with sequelae-EDSS/FS [% (n), 30 days post onset of relapse]^b	64.7 (235)	72.3 (264)	77.4 (277)	12 p = 0.0311	20 p = 0.0002	p = 0.124
Patients free of relapses with sequelae-investigator [% (n), end of relapse]^c	77.4 (281)	80.0 (292)	86.9 (311)	3 p = 0.42	12 p = 0.0009	p = 0.016
Patients free of relapses leading to hospitalization [% (n)]	80.4 (292)	86.0 (314)	90.8 (325)	7 p = 0.047	13 p < 0.0001	p = 0.049
Patients free of relapses requiring IV corticosteroids [% (n)]^d	55.1 (200)	62.5 (228)	66.5 (238)	13 p = 0.050	21 p = 0.002	p = 0.23

ITT intention to treat, IV intravenous, TEMSO TEriflunomide Multiple Sclerosis Oral

^aRelative change: a positive number indicates more patients free from relapse compared with placebo

^bIncomplete neurological recovery, defined by an increase in the Expanded Disability Status Scale (EDSS) or Functional system (FS) 30 days post relapse

^cIncomplete neurological recovery, as assessed by the investigator at the end of relapse

^dMissing data regarding intravenous (IV) corticosteroid use was reported in 12.6 % of relapses